about
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomasDissecting the genomic complexity underlying medulloblastomaCD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumorsGenome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibitionSlitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in miceDriver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastomaAngiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis.Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.Epigenomic alterations define lethal CIMP-positive ependymomas of infancyRecurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in miceTargeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.Histone deacetylase 10 promotes autophagy-mediated cell survival.Retinal angiogenesis suppression through small molecule activation of p53Targeting of HDAC8 and investigational inhibitors in neuroblastoma.Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.Molecular approaches to ependymoma: the next step(s).Emerging insights into the ependymoma epigenome.Targeting of histone deacetylases in brain tumors.Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis.Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing.GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastomaHD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor VorinostatNext-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance.Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.Nestin expression identifies ependymoma patients with poor outcome.PM-09ESTABLISHMENT AND MOLECULAR CHARACTERIZATION OF PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS.LG-27DKFZ-BT66 - A NOVEL PILOCYTIC ASTROCYTOMA MODEL FOR PRECLINICAL DRUG TESTING.MB-57INTERACTION OF HDAC2 AND MYC IN GROUP 3 MEDULLOBLASTOMA - A NOVEL THERAPEUTIC TARGET.PCM-16MOLECULAR CHARACTERIZATION OF ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS.Molecular staging of intracranial ependymoma in children and adults.
P50
Q24339074-96C58BE1-3509-43A6-8AEA-28077910A4DBQ24621907-82E21CC5-6BD2-479F-967F-975CAF34EB14Q24652007-6697ECBB-FF14-4506-849B-B0E58C5467D6Q27852966-428C2662-131A-4374-844E-DF3A24830F3BQ28511908-91555BE6-DC76-4DAB-A44D-7D810E240A3CQ29616862-AC3FD7B9-BABE-4E4F-8750-BD2BFC739A2DQ34113868-08FCC185-0153-4240-B3F6-B7B7264300ACQ34132926-96761661-691E-417B-AA5D-3121AD36A124Q34240198-B4E9B72D-E5FD-4457-BD48-C367CFBDE38AQ34354839-984CD38B-9AEA-4158-9BF0-3C1E75D6E8BCQ34515911-80AA4611-BE52-460C-B09D-398B22963923Q34755317-564BE692-B06B-4DFC-BB07-758A64A61752Q35246513-43248774-3E38-47F2-B0DE-2DCCD5ED5973Q35869744-3B3FE1BD-7FEB-4CC9-8FA6-565D8FF33EFCQ36347228-CFF60FED-CA0D-4939-B10E-6A47C44D6F67Q36901551-D5B3F632-7DE7-43DB-BB21-87EE80727B82Q37010515-2CE0A082-FA79-40D7-844A-96E065AFDB46Q37200838-73CAEA82-6A41-46A3-9F08-A99978F02FF1Q37603349-BDCB129A-57F8-4A96-AE2C-88B2F8930857Q37641698-4DD9EEDF-0E94-46A2-9573-DB5CE3D23B14Q37706929-05BD7EB7-49C7-4F8A-8AC9-2660B73F0109Q38046060-BE71FFA4-9672-4AB2-9426-E5C7858075CAQ38083798-371CF882-8D42-4D99-AFE8-EDD1398B7CD9Q38233117-45C813D6-DEAC-4A31-8836-0684DCF61D2FQ38961577-F6A2B9CE-D065-45D8-AFCF-55AA7D86AA8AQ38993103-4CE54D5F-1D95-4032-9341-CF83D6143070Q39034764-E5AE22F8-9B2E-4B51-90F9-8BC059FD83A7Q39158975-4BB3A287-57A4-4B34-9CF4-C31D304517BDQ39262034-DEBF034F-8EEB-4BA1-B59F-1C862FAEE0E0Q39485541-B8569854-6FE8-4839-AD04-64F6062E24B0Q39538403-BED8F43C-DA3A-44E9-A46D-97734CAF04C7Q39944234-9157765D-F5BC-4DD2-B0DB-9545B4F3B309Q41168233-1B3EF36D-5523-43DA-BE37-21C0A3B2AE5AQ41264935-B58E9370-9EBD-4E74-8730-E3BC1AA8BD2FQ43662312-E534F9A3-3062-4CB7-B04F-8B704E146330Q45957447-BD48A7D2-A0B7-43C9-A898-56176EEAE3B8Q46353091-E925138D-A890-4663-A0F8-AF6E0D9B791AQ46354960-241A376C-8FEE-4920-AD39-1910FD8201A6Q46357296-77A7D7B6-3706-4441-8625-97E04BB3648CQ46526605-82ABECE3-5869-4BFC-B75A-F05E442821AC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Till Milde
@ast
Till Milde
@en
Till Milde
@es
Till Milde
@nl
Till Milde
@sl
type
label
Till Milde
@ast
Till Milde
@en
Till Milde
@es
Till Milde
@nl
Till Milde
@sl
prefLabel
Till Milde
@ast
Till Milde
@en
Till Milde
@es
Till Milde
@nl
Till Milde
@sl
P106
P214
256153775036861550000
P31
P496
0000-0002-7267-1052
P734
P735
P7859
viaf-256153775036861550000